A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) (NCT05123703)
A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and \< 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks.
Who can join: Review the eligibility criteria below.
Location: UC San Diego — La Jolla, California
Age range: 10 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (71 Sites)
Showing the first 25 of 71 sites.
- UC San Diego — La Jolla, California
- Children's Hospital Colorado — Aurora, Colorado
- Children's National Hospital — Washington D.C., District of Columbia
- Johns Hopkins Medicine — Baltimore, Maryland
- Boston Children's Hospital Central Pharmacy — Boston, Massachusetts
- Washington University — St Louis, Missouri
- Cleveland Clinic, Mellen Center for Multiple Sclerosis — Cleveland, Ohio
- The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company — Columbus, Ohio
- The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Baylor College of Medicine/Texas Children's Hospital — Houston, Texas
- Centro de Investigaciones Médicas Tucuman — San Miguel de Tucumán,
- Royal Children's Hospital Melbourne - PIN — Parkville, Victoria
- Medizinische Universität Wien — Vienna,
- UZ Gent — Ghent,
- L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME — Brasília, Federal District
- Instituto de Neurologia de Curitiba — Curitiba, Paraná
- Nucleo de Pesquisa Clinica do Rio Grande do Sul NPCR — Porto Alegre, Rio Grande do Sul
- Hospital Sao Lucas - PUCRS — Porto Alegre, Rio Grande do Sul
- CPQuali Pesquisa Clínica Sao Paulo — São Paulo, São Paulo
- Inst. Da Criança- Faculdade de Medicina Usp — São Paulo,
- Children's Hospital of Eastern Ontario — Ottawa, Ontario
- The Hospital for Sick Children — Toronto, Ontario
- Astra Kliinik — Tallinn,
- Tartu University Hospital — Tartu,
- Hospices Civils de Lyon - Hôpital Pierre Wertheimer — Bron, Rhône
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsing-remitting Multiple Sclerosis
Explore by condition: All Relapsing-remitting Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.